| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 290.8 | 227.8 |
| Profit before tax | 49.0 | 33.8 |
| Net income | 35.1 | 26.6 |
| EPS (diluted, $ a share) | $1.51 | $1.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +32.1% |
|---|---|
| Revenue, year on year | +27.6% |
| Operating margin | 18.0% |
10-Q filed with the SEC, NASDAQ: ANIP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ani Pharmaceuticals Inc: key numbers
- Share price
- $70.89Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ani Pharmaceuticals Inc
All →Ani Pharmaceuticals Investor Presentation
ANI Pharmaceuticals published an updated corporate investor presentation for November 2026 to its website. The presentation outlines the company's strategic transformation into a leading rare disease company, including its proposed acquisition of Egetis Therapeutics and growth strategies for products like Cortrophin Gel and ILUVIEN.
Ani Pharmaceuticals Sr. VP, General Counsel & Sec. Meredith Cook Sells $35.4K of Stock
Meredith Cook, Sr. VP, General Counsel & Sec., sold 500 shares of Ani Pharmaceuticals Inc at $70.80 a share, worth $35.4K in total on Nov 13, 2026. Shares held after the trade: 72,924 (-0.7%).
- Value
- $35.4K
- Shares
- 500
- Price
- $70.80
- Role
- Sr. VP, General Counsel & Sec.
- Holding change
- -0.7%
- Trade date
- Nov 13, 2026
Ani Pharmaceuticals Signs $676M M&A Deal with Egetis Therapeutics AB
ANI Pharmaceuticals announced a recommended public cash offer to acquire all outstanding shares, convertibles, and warrants of Sweden-based Egetis Therapeutics AB. To finance the acquisition and refinance existing debt, ANI entered into a $676 million 364-day senior bridge credit facility with JPMorgan Chase Bank. The offer price is set at SEK 11.25 per share in cash.
- Value
- $676M
- Counterparty
- Egetis Therapeutics AB (publ)
Ani Pharmaceuticals Financial Results
ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, a 27.6% year-over-year increase driven by strong performance in its Rare Disease and Generics segments. The company narrowed its full-year revenue guidance and raised its adjusted EBITDA and EPS outlook while highlighting its pending acquisition of Egetis Therapeutics.
- Term
- Q3 2026
“In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company. Cortrophin Gel delivered solid growth, driven by momentum from the gout expansion and continued progress in our existing specialties, while our Generics business continued to outperform.”
Nikhil Lalwani, President and CEO of ANI
“As we head into the end of the year, we are focused on delivering our 2026 financial guidance and advancing the proposed acquisition of Egetis toward closing. We are also executing multiple operational and strategic initiatives to achieve approximately 40% year-over-year growth in 2026 for Cortrophin and capture the significant multi-year growth opportunity ahead.”
Nikhil Lalwani, President and CEO of ANI
Ani Pharmaceuticals SVP & CFO Stephen P. Carey Sells $208K of Stock
Stephen P. Carey, SVP & CFO, sold 2,850 shares of Ani Pharmaceuticals Inc at $72.87 a share, worth $208K in total on Oct 29, 2026. Shares held after the trade: 166,143 (-1.7%).
- Value
- $208K
- Shares
- 2,850
- Price
- $72.87
- Role
- SVP & CFO
- Holding change
- -1.7%
- Trade date
- Oct 29, 2026
Ani Pharmaceuticals President & CEO Nikhil Lalwani Sells $388K of Stock
Nikhil Lalwani, President & CEO, sold 5,400 shares of Ani Pharmaceuticals Inc at $71.89 a share, worth $388K in total on Oct 15, 2026. Shares held after the trade: 333,689 (-1.6%).
- Value
- $388K
- Shares
- 5,400
- Price
- $71.89
- Role
- President & CEO
- Holding change
- -1.6%
- Trade date
- Oct 15, 2026